Here, we have reported our initial clinical experience with the use of [99mTc]Tc-PSMA-T4 radiolabeled ligand in subjects with prostate cancer, which was initially and recently described by Sergieva et al. [34,35]. Here, CD4 is linked to prostate cancer.